ResearcherUnion HospitalActive in the last 2 years

Peng Lin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-3398-8864; OpenAlex author ID A5100439455. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2025: 1 paper · 2026: 1 paper

Papers 2

Multi-Omics and Computational Pharmacology Approach With Experimental Validation Reveals the Antiproliferative Activity of Sophoricoside Against Pancreatic Can… Co-author DOI 10.1002/cbdv.71778 ↗
aPD-L1-facilitated theranostic and tumor microenvironment remodeling of pancreatic cancer via docetaxel-loaded phase-transformation nanoparticles triggered by … Co-author DOI 10.1186/s12951-025-03105-7 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jing Li · 1 shared paper, 2026 · strength 0.43
- Paper Multi-Omics and Computational Pharmacology Approach With Experimental Validation Reveals the Antiproliferative Activity… DOI 10.1002/cbdv.71778 ↗
Wei Cheng · 1 shared paper, 2026 · strength 0.43
- Paper Multi-Omics and Computational Pharmacology Approach With Experimental Validation Reveals the Antiproliferative Activity… DOI 10.1002/cbdv.71778 ↗
Yi Tang · 1 shared paper, 2025 · strength 0.23
- Paper aPD-L1-facilitated theranostic and tumor microenvironment remodeling of pancreatic cancer via docetaxel-loaded phase-tr… DOI 10.1186/s12951-025-03105-7 ↗
Zhikui Chen · 1 shared paper, 2025 · strength 0.23
- Paper aPD-L1-facilitated theranostic and tumor microenvironment remodeling of pancreatic cancer via docetaxel-loaded phase-tr… DOI 10.1186/s12951-025-03105-7 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.